Advisory Committee; Veterinary Medicine Advisory Committee; Termination, 69991-69992 [2013-27854]
Download as PDF
Federal Register / Vol. 78, No. 226 / Friday, November 22, 2013 / Rules and Regulations
For the reasons discussed above, I
certify that this AD:
(1) Is not a ‘‘significant regulatory
action’’ under Executive Order 12866;
(2) Is not a ‘‘significant rule’’ under
DOT Regulatory Policies and Procedures
(44 FR 11034, February 26, 1979);
(3) Will not affect intrastate aviation
in Alaska to the extent that it justifies
making a regulatory distinction; and
(4) Will not have a significant
economic impact, positive or negative,
on a substantial number of small entities
under the criteria of the Regulatory
Flexibility Act.
We prepared an economic evaluation
of the estimated costs to comply with
this AD and placed it in the AD docket.
List of Subjects in 14 CFR Part 39
Air transportation, Aircraft, Aviation
safety, Incorporation by reference,
Safety.
Adoption of the Amendment
Accordingly, under the authority
delegated to me by the Administrator,
the FAA amends 14 CFR part 39 as
follows:
PART 39—AIRWORTHINESS
DIRECTIVES
1. The authority citation for part 39
continues to read as follows:
■
Authority: 49 U.S.C. 106(g), 40113, 44701.
§ 39.13
[Amended]
2. The FAA amends § 39.13 by adding
the following new airworthiness
directive (AD):
■
2013–23–09 Eurocopter France:
Amendment 39–17664; Docket No.
FAA–2013–0523; Directorate Identifier
2012–SW–091–AD.
(a) Applicability
This AD applies to Eurocopter France
(Eurocopter) Model AS350B, AS350BA,
AS350B1, AS350B2, AS350B3, AS350C,
AS350D, AS350D1, AS355E, AS355F,
AS355F1, AS355F2, AS355N, and AS355NP
helicopters with sliding doors installed,
except those with modification AL.4262,
certificated in any category.
ehiers on DSK2VPTVN1PROD with RULES
(b) Unsafe Condition
This AD defines the unsafe condition as
loss of the self-locking feature of the sliding
door lower ball-joint nut. This condition
could result in detachment of the lower balljoint bolt from the sliding door and
subsequent loss of the sliding door from the
helicopter in flight.
specified compliance time unless it has
already been accomplished prior to that time.
(e) Required Actions
(1) Within 165 hours time-in-service,
remove each nut, part number (P/N)
ASN52320BH060N, and each washer, P/N
23111AG0LE, from the left-hand and righthand sliding door lower ball-joint bolts and
replace them with an airworthy nut and
washer.
(2) Do not install a nut, P/N
ASN52320BH060N, or washer, P/N
23111AG0LE, on any sliding door lower balljoint bolt.
(f) Special Flight Permits
Special flight permits are prohibited.
(g) Alternative Methods of Compliance
(AMOCs)
(1) The Manager, Safety Management
Group, FAA, may approve AMOCs for this
AD. Send your proposal to: Robert Grant,
Aviation Safety Engineer, Safety Management
Group, FAA, 2601 Meacham Blvd., Fort
Worth, Texas 76137; telephone 817–222–
5110; email robert.grant@faa.gov.
(2) For operations conducted under a 14
CFR part 119 operating certificate or under
14 CFR part 91, subpart K, we suggest that
you notify your principal inspector, or
lacking a principal inspector, the manager of
the local flight standards district office or
certificate holding district office, before
operating any aircraft complying with this
AD through an AMOC.
(h) Additional Information
(1) Eurocopter Alert Service Bulletin (ASB)
No. AS350–52.00.34 for Model AS350B, B1,
B2, B3, BA, BB and D and L1 helicopters and
ASB No. AS355–52.00.26 for Model AS355E,
F, F1, F2, N, and NP helicopters, both
Revision 0 and both dated July 9, 2012,
which are not incorporated by reference,
contain additional information about the
subject of this AD. For service information
identified in this AD, contact American
Eurocopter Corporation, 2701 N. Forum
Drive, Grand Prairie, TX 75052; telephone
(972) 641–0000 or (800) 232–0323; fax (972)
641–3775; or at https://www.eurocopter.com/
techpub. You may review the referenced
service information at the FAA, Office of the
Regional Counsel, Southwest Region, 2601
Meacham Blvd., Room 663, Fort Worth,
Texas 76137.
(2) The subject of this AD is addressed in
European Aviation Safety Agency (EASA) AD
No. 2012–0205, dated October 1, 2012. You
may view the EASA AD on the internet in
AD Docket No. FAA–2013–0523 at https://
www.regulations.gov.
(i) Subject
Joint Aircraft Service Component (JASC)
Code: 5200: Doors.
(c) Effective Date
This AD becomes effective December 27,
2013.
(d) Compliance
You are responsible for performing each
action required by this AD within the
Issued in Fort Worth, Texas, on November
5, 2013.
Lance T. Gant,
Acting Directorate Manager, Rotorcraft
Directorate, Aircraft Certification Service.
[FR Doc. 2013–27636 Filed 11–21–13; 8:45 am]
VerDate Mar<15>2010
14:00 Nov 21, 2013
Jkt 232001
BILLING CODE 4910–13–P
PO 00000
Frm 00009
Fmt 4700
Sfmt 4700
69991
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
21 CFR Part 14
[Docket No. FDA–2013–N–1380]
Advisory Committee; Veterinary
Medicine Advisory Committee;
Termination
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Final rule.
The Food and Drug
Administration (FDA) is announcing the
termination of the Veterinary Medicine
Advisory Committee. This document
removes the Veterinary Advisory
Committee from the Agency’s list of
standing advisory committees.
DATES: This rule is effective November
22, 2013.
FOR FURTHER INFORMATION CONTACT:
Michael Ortwerth, Advisory Committee
Oversight and Management Staff, Food
and Drugs Administration, 10903 New
Hampshire Ave., Bldg. 32, Rm. 5129,
Silver Spring MD 20993–0002, FAX:
301–847–8640, or email at
Michael.Ortwerth@fda.hhs.gov.
SUPPLEMENTARY INFORMATION: The
Veterinary Medicine Committee was
established on April 24, 1984 (49 FR
20809; May 17, 1984). The purpose of
the Committee was to review and
evaluate available data concerning
safety and effectiveness of marketed and
investigational new animal drugs, feeds,
and devices for use in the treatment and
prevention of animal diseases and
increased animal production. The
Committee is no longer needed and was
terminated on September 24, 2013.
Under 5 U.S.C. 553(b)(3)(B) and (d)
and 21 CFR 10.40 (d) and (e), the
Agency finds good cause to dispense
with notice and public comment
procedures and to proceed to an
immediate effective date on this rule.
Notice and public comment and a
delayed effective date are unnecessary
and are not in the public interest as this
final rule merely removes the name of
the Veterinary Medicine Advisory
Committee from the list of FDA’s
standing advisory committees in 21 CFR
14.100.
Therefore, the Agency is amending 21
CFR 14.100(f) as set forth in the
regulatory text of this document.
SUMMARY:
List of Subjects in 21 CFR Part 14
Administrative practice and
procedure, Advisory committees, Color
additives, Drugs, Radiation protection.
E:\FR\FM\22NOR1.SGM
22NOR1
69992
Federal Register / Vol. 78, No. 226 / Friday, November 22, 2013 / Rules and Regulations
Therefore, under the Federal Food,
Drug, and Cosmetic Act and under
authority delegated to the Commissioner
of Food and Drugs, 21 CFR part 14 is
amended as follows:
PART 14—PUBLIC HEARING BEFORE
A PUBLIC ADVISORY COMMITTEE:
1. The authority citation for 21 CFR
part 14 continues to read as follows:
■
Authority: 5 U.S.C. App. 2; 15 U.S.C.
1451–1461, 21 U.S.C. 41–50, 141–149, 321–
394, 467f, 679, 821, 1034; 28 U.S.C. 2112; 42
U.S.C. 201, 262, 263b, 264; Pub. L. 107–109;
Pub. L. 108–155.
§ 14.100
[Amended]
2. Section 14.100 is amended by
removing paragraph (f) and
redesignating paragraph (g) as paragraph
(f).
■
Dated: November 14, 2013.
Jill Hartzler Warner,
Acting Associate Commissioner for Special
Medical Programs.
BILLING CODE 4160–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
21 CFR Part 123
[Docket No. FDA–2013–D–0269]
Guidance for Industry on Purchasing
Reef Fish Species Associated With the
Hazard of Ciguatera Fish Poisoning;
Availability
Food and Drug Administration,
HHS.
ACTION:
Notice of availability.
The Food and Drug
Administration (FDA or we) is
announcing the availability of a
guidance for industry entitled
‘‘Guidance for Industry: Purchasing Reef
Fish Species Associated with the
Hazard of Ciguatera Fish Poisoning.’’
The document provides guidance to
primary seafood processors who
purchase reef fish on how to minimize
the risk of ciguatera fish poisoning
(CFP) from fish that they distribute. The
guidance intends to help protect the
public health by reducing the risk of
CFP.
ehiers on DSK2VPTVN1PROD with RULES
SUMMARY:
Submit either electronic or
written comments on FDA guidances at
any time.
ADDRESSES: Submit written requests for
single copies of the guidance to Division
of Seafood Safety/Office of Food Safety,
DATES:
VerDate Mar<15>2010
14:00 Nov 21, 2013
Jkt 232001
Dockets Management (see ADDRESSES). It
is only necessary to send one set of
comments. Identify comments with the
docket number found in brackets in the
heading of this document. Received
comments may be seen in the Division
of Dockets Management between 9 a.m.
and 4 p.m., Monday through Friday, and
will be posted to the docket at https://
www.regulations.gov.
III. Electronic Access
Persons with access to the Internet
may obtain the guidance at either https://
www.fda.gov/FoodGuidances or https://
www.regulations.gov. Use the FDA Web
site listed in the previous sentence to
find the most current version of the
guidance.
Dated: November 15, 2013.
Leslie Kux,
Assistant Commissioner for Policy.
[FR Doc. 2013–27913 Filed 11–21–13; 8:45 am]
BILLING CODE 4160–01–P
I. Background
[FR Doc. 2013–27854 Filed 11–21–13; 8:45 am]
AGENCY:
Center for Food Safety and Applied
Nutrition, (HFS–325), Food and Drug
Administration, 5100 Paint Branch
Pkwy., College Park, MD 20740. Send
two self-addressed adhesive labels to
assist that office in processing your
request. See the SUPPLEMENTARY
INFORMATION section for electronic
access to the guidance.
Submit electronic comments on the
guidance to https://www.regulations.gov.
Submit written comments on the
guidance to the Division of Dockets
Management (HFA–305), Food and Drug
Administration, 5630 Fishers Lane, rm.
1061, Rockville, MD 20852.
FOR FURTHER INFORMATION CONTACT:
Karen Swajian, Division of Seafood
Safety, Center for Food Safety and
Applied Nutrition (HFS–325), Food and
Drug Administration, 5100 Paint Branch
Pkwy., College Park, MD 20740, 240–
402–2300.
SUPPLEMENTARY INFORMATION:
We are announcing the availability of
a guidance for industry entitled
‘‘Guidance for Industry: Purchasing Reef
Fish Species Associated with the
Hazard of Ciguatera Fish Poisoning.’’
This guidance is being issued consistent
with our good guidance practices
regulation (21 CFR 10.115). The
guidance represents our current
thinking on this topic. It does not create
or confer any rights for or on any person
and does not operate to bind FDA or the
public. An alternative approach may be
used if such approach satisfies the
requirements of the applicable statutes
and regulations.
In the Federal Register of March 26,
2013 (78 FR 18273), FDA made
available a draft guidance entitled
‘‘Guidance for Industry: Purchasing Reef
Fish Species Associated with the
Hazard of Ciguatera Fish Poisoning’’
and gave interested parties an
opportunity to submit comments by
May 28, 2013, for us to consider before
beginning work on the final version of
the guidance. We received three
comments on the draft guidance, but the
comments did not prompt us to revise
the guidance. Therefore, we are issuing
the guidance with minor changes
(revising dates mentioned in the
guidance to reflect the most current
information). The guidance announced
in this notice finalizes the draft
guidance dated March 2013.
II. Comments
Interested persons may submit either
electronic comments regarding the
guidance to https://www.regulations.gov
or written comments to the Division of
PO 00000
Frm 00010
Fmt 4700
Sfmt 4700
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
21 CFR Part 558
[Docket No. FDA–2013–N–0002]
Withdrawal of Approval of New Animal
Drug Applications; Carbarsone;
Roxarsone
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Final rule.
The Food and Drug
Administration (FDA) is amending the
animal drug regulations to reflect the
withdrawal approval of three new
animal drug applications (NADAs) for
roxarsone or carbarsone Type A
medicated articles at the sponsor’s
request because the products are no
longer manufactured or marketed.
DATES: This rule is effective December 2,
2013.
FOR FURTHER INFORMATION CONTACT: John
Bartkowiak, Center for Veterinary
Medicine (HFV–212), Food and Drug
Administration, 7519 Standish Pl.,
Rockville, MD 20855, 240–276–9079,
john.bartkowiak@fda.hhs.gov.
SUPPLEMENTARY INFORMATION: Zoetis
Inc., 333 Portage St., Kalamazoo, MI
49007, has requested that FDA
withdraw approval of the following
three NADAs because the products,
used to manufacture Type B and Type
C medicated feeds, are no longer
manufactured or marketed: NADA 007–
891 for 3–NITRO (roxarsone) Type A
SUMMARY:
E:\FR\FM\22NOR1.SGM
22NOR1
Agencies
[Federal Register Volume 78, Number 226 (Friday, November 22, 2013)]
[Rules and Regulations]
[Pages 69991-69992]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2013-27854]
=======================================================================
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
21 CFR Part 14
[Docket No. FDA-2013-N-1380]
Advisory Committee; Veterinary Medicine Advisory Committee;
Termination
AGENCY: Food and Drug Administration, HHS.
ACTION: Final rule.
-----------------------------------------------------------------------
SUMMARY: The Food and Drug Administration (FDA) is announcing the
termination of the Veterinary Medicine Advisory Committee. This
document removes the Veterinary Advisory Committee from the Agency's
list of standing advisory committees.
DATES: This rule is effective November 22, 2013.
FOR FURTHER INFORMATION CONTACT: Michael Ortwerth, Advisory Committee
Oversight and Management Staff, Food and Drugs Administration, 10903
New Hampshire Ave., Bldg. 32, Rm. 5129, Silver Spring MD 20993-0002,
FAX: 301-847-8640, or email at Michael.Ortwerth@fda.hhs.gov.
SUPPLEMENTARY INFORMATION: The Veterinary Medicine Committee was
established on April 24, 1984 (49 FR 20809; May 17, 1984). The purpose
of the Committee was to review and evaluate available data concerning
safety and effectiveness of marketed and investigational new animal
drugs, feeds, and devices for use in the treatment and prevention of
animal diseases and increased animal production. The Committee is no
longer needed and was terminated on September 24, 2013.
Under 5 U.S.C. 553(b)(3)(B) and (d) and 21 CFR 10.40 (d) and (e),
the Agency finds good cause to dispense with notice and public comment
procedures and to proceed to an immediate effective date on this rule.
Notice and public comment and a delayed effective date are unnecessary
and are not in the public interest as this final rule merely removes
the name of the Veterinary Medicine Advisory Committee from the list of
FDA's standing advisory committees in 21 CFR 14.100.
Therefore, the Agency is amending 21 CFR 14.100(f) as set forth in
the regulatory text of this document.
List of Subjects in 21 CFR Part 14
Administrative practice and procedure, Advisory committees, Color
additives, Drugs, Radiation protection.
[[Page 69992]]
Therefore, under the Federal Food, Drug, and Cosmetic Act and under
authority delegated to the Commissioner of Food and Drugs, 21 CFR part
14 is amended as follows:
PART 14--PUBLIC HEARING BEFORE A PUBLIC ADVISORY COMMITTEE:
0
1. The authority citation for 21 CFR part 14 continues to read as
follows:
Authority: 5 U.S.C. App. 2; 15 U.S.C. 1451-1461, 21 U.S.C. 41-
50, 141-149, 321-394, 467f, 679, 821, 1034; 28 U.S.C. 2112; 42
U.S.C. 201, 262, 263b, 264; Pub. L. 107-109; Pub. L. 108-155.
Sec. 14.100 [Amended]
0
2. Section 14.100 is amended by removing paragraph (f) and
redesignating paragraph (g) as paragraph (f).
Dated: November 14, 2013.
Jill Hartzler Warner,
Acting Associate Commissioner for Special Medical Programs.
[FR Doc. 2013-27854 Filed 11-21-13; 8:45 am]
BILLING CODE 4160-01-P